Gossamer Bio (GOSS)
(Delayed Data from NSDQ)
$1.05 USD
+0.06 (6.45%)
Updated Oct 1, 2024 04:00 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GOSS 1.05 +0.06(6.45%)
Will GOSS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for GOSS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GOSS
Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
GOSS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?
Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
What Makes Gossamer Bio (GOSS) a New Buy Stock
Other News for GOSS
Gossamer Bio management to meet with Oppenhiemer
Presenting on the Emerging Growth Conference 75 Day 2 on September 26
Bullish Outlook on Gossamer Bio’s Seralutinib Efficacy and Market Potential
Gossamer Bio (GOSS) Receives a Buy from Oppenheimer
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss